- Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage failWhile Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset showed significant superiority at day 15.BioSpace · 1h ago↗ source
- Boehringer Ingelheim pauses Phase 1 study of oral candidate BI 3031185 after safety eventBoehringer Ingelheim has placed a Phase 1 study of its oral candidate BI 3031185 on hold after a safety event was identified. The trial, run in Japan with healthy volunteers, was assessing tolerab…